[CITATION][C] Rapamycin's resurrection: a new way to target the cancer cell cycle
K Garber - Journal of the National Cancer Institute, 2001 - academic.oup.com
K Garber
Journal of the National Cancer Institute, 2001•academic.oup.comCCI-779, a close analogue of rapamycin, has shown activity against a wide range of cancers
in preclinical models and in phase I trials, and seven different phase II trials are under way.
Some suggest that it may be one of the most promising drugs in the anticancer pipeline.“I'm
excited,” said Charles Sawyers, MD, of the University of California at Los Angeles Jonsson
Comprehensive Cancer Center.“It'sa safe drug, it's very precise in its action, it's definitely a
targeted therapy.”
in preclinical models and in phase I trials, and seven different phase II trials are under way.
Some suggest that it may be one of the most promising drugs in the anticancer pipeline.“I'm
excited,” said Charles Sawyers, MD, of the University of California at Los Angeles Jonsson
Comprehensive Cancer Center.“It'sa safe drug, it's very precise in its action, it's definitely a
targeted therapy.”
CCI-779, a close analogue of rapamycin, has shown activity against a wide range of cancers in preclinical models and in phase I trials, and seven different phase II trials are under way. Some suggest that it may be one of the most promising drugs in the anticancer pipeline.
“I’m excited,” said Charles Sawyers, MD, of the University of California at Los Angeles Jonsson Comprehensive Cancer Center.“It’sa safe drug, it’s very precise in its action, it’s definitely a targeted therapy.”
Oxford University Press